Best for: Muscle injuries, multiple concurrent injuries, systemic inflammation Distribution: Whole-body via bloodstream Dosing frequency: Twice weekly during loading, once weekly maintenance Half-life: 24 to 48 hours Unique benefit: Reaches all injury sites from single injection Human Clinical Evidence Human clinical trials for Tb-500 remain remarkably sparse given its widespread underground use, but more data exists than for Bpc-157
Hormonal effects Unlike growth hormone secretagogues or compounds affecting testosterone and hormonal systems , epitalon does not appear to significantly alter hormone levels or cause endocrine disruption beyond its effects on melatonin
Clinical data support administration on the same day or in the same injection (if mixed), no proven pharmacokinetic interactions
GHK-Cu shelf life depends heavily on storage conditions
Delivery methodsMesotherapy/electroporation, iontophoresis, microneedling, topical
Phase 3 monotherapy available Feature Expected GI burden Cagrilintide + Retatrutide Very high CagriSema (Cag + Sema) High Retatrutide Alone High Feature Dysesthesia risk Cagrilintide + Retatrutide Yes (retatrutide component) CagriSema (Cag + Sema) No Retatrutide Alone Yes Feature Injections per week Cagrilintide + Retatrutide 2 (separate) or 1 (pre-blend) CagriSema (Cag + Sema) 1 or 2 Retatrutide Alone 1 Feature Regulatory status Cagrilintide + Retatrutide Neither approved
